LGR5 and neuroblastoma: Comparison of our 90 DEGs with mutations identified in this study further revealed that 9 of our Wnt targets (10%) also exhibited mutations in neuroblastoma; these included ADAMTS14, AXIN2, CACHD1, DUSP4, IRF2BP2, NPY2R, NRP2, OPRM1, and ZNRF3. In addition, LGR5 was also mutated in one sample, adding to the previously reported LGR5 mutations [13].